Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) generates frequent news related to its development of immuno-pharma therapeutics, particularly its flagship product candidate Ampligen (rintatolimod). Company announcements emphasize research and development in cancers, viral diseases, immune-deficiency disorders, and cancers with unmet medical needs, as well as updates on its intellectual property portfolio and corporate actions.
News coverage for AIM ImmunoTech often focuses on clinical and scientific milestones. Recent communications describe progress in the DURIPANC clinical program, where Ampligen is evaluated in combination with AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer, and presentations of data from a completed Phase 2 study in advanced recurrent ovarian cancer combining Ampligen with cisplatin and Merck’s Keytruda (pembrolizumab). The company also highlights publications in peer-reviewed journals and abstracts accepted at major scientific meetings such as the Society for Immunotherapy of Cancer (SITC).
Another recurring theme in AIM’s news is the expansion of its intellectual property. The company has announced a European patent covering compositions of its proprietary dsRNAs, including Ampligen, for treating Long COVID, and a patent in Japan for using Ampligen with checkpoint inhibitors for cancer treatment. These updates are presented as part of AIM’s strategy to strengthen protection around Ampligen in oncology and post‑COVID indications.
Investors following AIM ImmunoTech’s news will also see items on financial and corporate developments, including stock dividends, participation in investor conferences, public offerings of common stock and warrants, and financing agreements such as a promissory note with an institutional investor. Regular news releases on quarterly financial results, capital-raising transactions, and shareholder meetings provide additional context on the company’s operations and governance.
This news page aggregates such announcements so readers can review AIM ImmunoTech’s clinical updates, patent developments, financing activities, and corporate communications in one place.
On March 8, 2023, AIM ImmunoTech (NYSE American: AIM) announced the publication of new data demonstrating that its drug Ampligen (rintatolimod) effectively inhibits the Ebola virus. Published in Antiviral Research, the study indicates that Ampligen offers a dual mechanism of action: enhancing innate immune responses and inactivating the EBOV lethal factor. Prior research showed 100% protection in a mouse model. Ampligen holds Orphan Drug Designation for Ebola from both the European Medicines Agency and the FDA, offering market exclusivity upon approval. AIM plans to file Investigational New Drug applications to explore Ampligen's use for Ebola treatment and prevention.
AIM ImmunoTech (AIM) reported significant operational and clinical advancements in its 2022 stockholder letter, highlighting successful trials for various cancer therapies and a commitment to future milestones. In 2022, AIM achieved several key developments, including IND clearance for a Phase 2 study targeting advanced pancreatic cancer and positive data from its clinical programs. The company is positioned to pursue multiple regulatory milestones in 2023, including commencing Phase 2 studies for post-COVID conditions and locally advanced pancreatic cancer. AIM emphasizes continued engagement with investors and scientific communities, showcasing a strategy for advancing clinical pipelines as it aims to deliver long-term stakeholder value.
AIM ImmunoTech Inc. (NYSE American: AIM) has announced the opening of its first clinical site for the AMP-270 Phase 2 study, evaluating Ampligen for locally advanced pancreatic cancer (LAPC). This randomized study compares the efficacy of Ampligen to a no-treatment control after FOLFIRINOX therapy. The trial aims to enroll approximately 90 subjects across 30 centers in the U.S. and Europe. CEO Thomas K. Equels emphasized the potential of Ampligen to set a new standard of care for LAPC, highlighting ongoing recruitment efforts at prominent cancer institutions.
AIM ImmunoTech Inc. (NYSE American: AIM) announced its participation in a virtual event on February 21, 2023, titled “Long Covid: What Will It Take To Accelerate Therapeutic Progress?” The event seeks to advance research on Long Covid and related diseases. CEO Thomas K. Equels will discuss the clinical development of Ampligen for ME/CFS and Long COVID. Preliminary results from Ampligen's treatment of Long COVID patients showed a statistically significant reduction in fatigue (p=0.002). The FDA has cleared AIM for a Phase 2 study of Ampligen for Post-COVID Conditions, with patient enrollment expected to begin in Q1 2023.
AIM ImmunoTech has entered a research collaboration with AstraZeneca and Erasmus MC to evaluate the efficacy of Ampligen® (rintatolimod) combined with Imfinzi (durvalumab) for treating metastatic pancreatic cancer. The clinical study, DURIPANC, will explore the synergistic potential of these therapies. Ampligen has previously shown promising results when used with PD-1 checkpoint inhibitors, and the partnership aims to address the significant unmet medical need in this area. AIM is actively pursuing clinical studies to promote Ampligen's application across various cancer types.
AIM ImmunoTech (NYSE American: AIM) announced the granting of a utility patent by the Netherlands Patent Office for its double-stranded RNA product, rugged dsRNA, linked to Ampligen® (rintatolimod). This patent extends AIM's portfolio for COVID-19 treatments. Ampligen is designed to enhance the immune system's response, showing significant impact on SARS-CoV-2 viral replication. The company is also conducting early access programs and Phase 2 clinical studies for Ampligen in pancreatic cancer, alongside ongoing trials for various solid tumors.
AIM ImmunoTech Inc. (NYSE American: AIM) announced a live video webcast presentation by CEO Thomas K. Equels at the Virtual Investor 2023 Companies to Watch Event on January 18, 2023, at 11:00 AM ET. The company focuses on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. Its leading product, Ampligen®, is currently in clinical trials for pancreatic cancer and approved for treating chronic fatigue syndrome in Argentina. A replay of the webcast will be available on the company’s website for 90 days.
AIM ImmunoTech (NYSE American: AIM) has promoted Christopher McAleer, Ph.D., to Scientific Officer, reflecting his contributions since joining as Deputy Scientific Officer in June 2022. CEO Thomas K. Equels emphasized McAleer's vital role in advancing AIM's clinical development programs, particularly with the drug Ampligen. McAleer brings extensive experience from his previous role at Hesperos, where he significantly increased operational scale. AIM's Ampligen is currently in clinical trials for various cancers and approved for use in treating severe chronic fatigue syndrome.
AIM ImmunoTech (AIM) recently presented data at the British Society for Immunology Congress 2022 regarding the safety and efficacy of its intranasal treatment, Ampligen (rintatolimod). The study found that Ampligen was well-tolerated among healthy subjects, with no severe adverse events reported. The treatment potentially inhibits respiratory viruses, including SARS-CoV-2. Results indicated positive immune responses and support further development of Ampligen as a prophylactic option for respiratory infections.
AIM ImmunoTech Inc. (NYSE American: AIM) announced its abstract acceptance for poster presentation at the British Society for Immunology Congress 2022, scheduled for December 5-8, 2022, in Liverpool, UK. The poster, titled Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen, will be presented by Lisanne C.A. Smidt on December 7. Ampligen is currently in clinical trials for various conditions, including pancreatic cancer and COVID-19-related syndromes.